Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 23, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

June 30, 2026

Conditions
Anti-NMDAR Encephalitis
Interventions
DRUG

IA session

10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.

DRUG

Rituximab

"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~* at least 1 day before each IA session~* the last injection will occur after the last session IA (minimum one day after)"

Trial Locations (1)

75015

RECRUITING

Hôpital Necker Enfants-Malades, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER